Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGB | P11216 | 3/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | LGALS8 | O00214 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | SLC28A3 | Q9HAS3 | 2/20 | 0.44 |
| ▸ | TYR | P14679 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4394977 | 1.00 | PYGB (0.51) | PYGBL3MBTL1LGALS8MAPTGAA | |
| SCHEMBL23867560 | 1.00 | PYGB (0.51) | PYGBL3MBTL1LGALS8MAPTGAA | |
| SCHEMBL28453329 | 0.84 | PYGB (0.50) | PYGBL3MBTL1LGALS8MAPTGAA | |
| SCHEMBL28463195 | 0.84 | PYGB (0.50) | PYGBL3MBTL1LGALS8MAPTGAA | |
| SCHEMBL29217350 | 0.84 | PYGB (0.50) | PYGBL3MBTL1LGALS8MAPTGAA | |
| SCHEMBL28902343 | 0.84 | PYGB (0.50) | PYGBL3MBTL1LGALS8MAPTGAA | |
| SCHEMBL7211096 | 0.81 | PYGB (0.53) | PYGBL3MBTL1LGALS8MAPTGAA | |
| SCHEMBL17523750 | 0.81 | SLC28A3 (0.50) | PYGBL3MBTL1LGALS8MAPTGAA | |
| SCHEMBL22047951 | 0.81 | SLC28A3 (0.50) | PYGBL3MBTL1LGALS8MAPTGAA | |
| SCHEMBL22026379 | 0.81 | SLC28A3 (0.50) | PYGBL3MBTL1LGALS8MAPTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1742962-B1 | METHODS AND KITS FOR FOLDING PROTEINS IN THE PRESENCE OF LINEAR OR BRANCHED SUGAR POLYMERS | EXPEDEON LTD (GB) | 2016-11-23 | — | — | EP | disclosed |
| EP-1749018-B1 | METHODS AND KITS FOR STABILISING, PROTECTING AND SOLUBILISING PROTEINS | EXPEDEON LTD (GB) | 2014-10-22 | — | — | EP | disclosed |
| US-20120115772-A1 | CONJUGATION METHOD | POLYTHERICS LIMITED (GB) | 2012-05-10 | — | — | US | disclosed |
| US-8119615-B2 | Incubating in an aqueous solution of a sugar polymer or sugar polymer derivative, such as inulin derivatized with urethane groups; improves yield of native protein in genetic engineering | EXPEDEON LIMITED (GB) | 2012-02-21 | — | — | US | disclosed |
| US-20080281085-A1 | Methods And Kits For Folding Proteins | NOVEXIN LIMITED (GB) | 2008-11-13 | — | — | US | disclosed |
| US-20080161230-A1 | Methods and Kits for Stabilising, Protecting and Solubilising Proteins | NOVEXIN LIMITED (GB) | 2008-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115772-A1 | CONJUGATION METHOD | INF2, INHA, ALB | PYGB 804/4885L3MBTL1 4492/4885LGALS8 2270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.